Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipiwutide ophthalmic solution for allergic conjunctivitis
CTR20211846Phase 2Suspended
- Sponsor
- Wuhan Yicheng Biotechnology
- Start
- Aug 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of ipiwutide in allergic conjunctivitis (AC), sponsored by Wuhan Yicheng Biotechnology. Started Aug 2021; status: suspended.
02
Drugs
ipiwutide
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on CTR20211846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211846.